Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04905914 · ClinicalTrials.gov registry record · Phase 1
Study Of ATRN-119 In Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Aprea Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 7
- Study locations
NCT04905914: Active Phase 1 study of Advanced Solid Tumor, sponsored by Aprea Therapeutics.
NCT04905914 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by Aprea Therapeutics. The registered enrollment target is 132 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (31% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04905914, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Aprea Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
Primary Outcome
Treatment-emergent AEs (TEAEs) will be collected and Clinical Laboratory Evaluations will be performed
Conditions Studied
Interventions
- DRUG ATRN-119
Study Locations (7)
Texas
- Mary Crowley Cancer Research - Dallas
- NEXT- Oncology Dallas - Irving
- NEXT Oncology- San Antonio - San Antonio
Connecticut
- Yale Cancer Center - New Haven
Ohio
- University Hospitals, Cleveland Medical Center - Cleveland
Pennsylvania
- Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine - Philadelphia
Virginia
- NEXT Oncology- Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What the registry record for NCT04905914 still lists
NCT04905914 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ATRN-119 is the first listed.
NCT04905914 lists 7 locations in 5 states (Texas, Connecticut, Ohio).
Frequently Asked Questions
What is clinical trial NCT04905914 about?
NCT04905914 is a clinical study titled "Study Of ATRN-119 In Patients With Advanced Solid Tumors". The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
What is the current status of trial NCT04905914?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2023-01-09. Estimated completion is 2028-02.
What conditions does trial NCT04905914 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT04905914?
The interventions under investigation include: ATRN-119 (DRUG).
Who is sponsoring clinical trial NCT04905914?
This trial is sponsored by Aprea Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04905914 being conducted?
This trial has 7 study locations across Connecticut, Ohio, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04905914's enrollment target sits among peer trials
132 98th of 189 higher than 91 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI